| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $511K | — | -67.0% |
| SG&A Expense | $1.1M | — | +26.7% |
| Operating Income | -$1.9M | — | +24.9% |
| Pre-tax Income | -$1.2M | — | -10.5% |
| Net Income | -$1.2M | — | -10.5% |
| EPS (Basic) | -$0.19 | — | +47.2% |
| EPS (Diluted) | -$0.19 | — | +47.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.1M | +14.2% | +1439.5% |
| Short-term Investments | $11.8M | -20.0% | +104.1% |
| Current Assets | $13.7M | -17.3% | +102.2% |
| Total Assets | $38.3M | -7.0% | +103.9% |
| Current Liabilities | $3.7M | -33.3% | -25.3% |
| Total Liabilities | $14.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.3M | — | -24.5% |
| Investing Cash Flow | $3.0M | — | +17.0% |
| Financing Cash Flow | $454K | — | — |
| +195.6% |
| Stockholders' Equity | $20.7M | -4.7% | +138.4% |